Integra LifeSciences (NASDAQ:IART) Upgraded to Buy at Argus

Integra LifeSciences (NASDAQ:IART - Get Free Report) was upgraded by research analysts at Argus from a "hold" rating to a "buy" rating in a research report issued on Monday, MarketBeat Ratings reports.

Separately, Morgan Stanley started coverage on Integra LifeSciences in a report on Monday, December 2nd. They issued an "underweight" rating and a $20.00 price target on the stock. Three analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $23.00.

Integra LifeSciences Stock Performance

Shares of IART stock traded down $0.63 on Monday, hitting $19.43. 228,853 shares of the stock traded hands, compared to its average volume of 1,041,393. The company has a market capitalization of $1.50 billion, a PE ratio of -215.81, a PEG ratio of 0.73 and a beta of 1.23. The company's fifty day moving average is $23.50 and its 200 day moving average is $22.25. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $34.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million for the quarter, compared to analysts' expectations of $445.15 million. During the same period in the prior year, the company earned $0.89 earnings per share. The firm's revenue was up 11.5% compared to the same quarter last year. On average, equities research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC increased its stake in shares of Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 1,371 shares during the period. Sterling Capital Management LLC increased its position in shares of Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after purchasing an additional 1,931 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after buying an additional 2,800 shares in the last quarter. Covestor Ltd lifted its holdings in shares of Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after buying an additional 2,071 shares during the period. Finally, Empowered Funds LLC bought a new position in Integra LifeSciences during the fourth quarter valued at about $180,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.